Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

22.04.2008

To ensure the best possible comparability, the first-quarter figures 
of 2007 are shown on a pro forma basis and adjusted for extraordinary
expenses.

Within the first three months of 2008, the Sartorius Group increased 
sales revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn). 
Currency-adjusted consolidated sales revenue climbed 7.7%. The 
Biotechnology Division's sales revenue rose 5.4% (currency-adjusted: 
+9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn). Sales revenue for the 
Mechatronics Division grew 1.5% (currency-adjusted: +5.1%) to EUR58.6
million (Q1 2007: EUR57.7 mn).

At EUR162.5 million, order intake was higher than sales revenue and 
thus at the high level of the year-earlier quarter (EUR162.9 mn). On 
the basis of constant currencies, order intake rose 3.4%. The 
difference between sales revenue and order intake essentially 
resulted from the fluctuations in the equipment business of the 
Biotechnology Division. The Division's order intake was EUR97.6 
million (Q1 2007: EUR99.1 million), which corresponds to a decline of
1.5% or a currency-adjusted increase of 2.2%. The value of orders for
the Mechatronics Division rose 1.8% or by a currency-adjusted rate of
5.3%.

First-quarter operating earnings (earnings before interest, taxes and
amortization = EBITA) increased from EUR11.8 million to EUR12.2 
million. At 8.2%, the EBITA margin remained unchanged compared to the
year-earlier figure. If the EBITA margin had been calculated based on
the previous year's exchange rates, it would have increased to more 
than 9%. EBITA for the Biotechnology Division rose from EUR8.4 
million to EUR9.1; for the Mechatronics Division, EBITA at EUR3.1 
million was below the year-earlier figure of EUR3.4 million. Net 
profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5 
million); earnings per share (excluding the two non-cash items of 
amortization and interest on share price warrants granted) were 
EUR0.25 (Q1 2007: EUR0.26).

For the full fiscal year of 2008, the Sartorius Group is continuing 
to aim at achieving sales revenue growth of more than 9% in constant 
currencies. Based on this anticipated sales revenue and on an average
exchange rate of 1.40 USD/EUR, the Group is planning to increase the 
EBITA margin to approx. 12%.

|EUR in millions                |Q1 2008 |Q1 2007   |Change     |
|(unless otherwise specified)   |        |pro forma |in %       |
|                               |        |          |           |
|Sartorius Group                |        |          |           |
|Sales revenue                  |149.2   |143.6     |+3.8 (+7.7)|
|Order intake                   |162.5   |162.9     |-0.2 (+3.4)|
|EBITA 1)                       |12.2    |11.8      |+3.7       |
|Net profit for the period 1)2) |4.2     |4.4       |-2.9       |
|Earnings per share 1)2) in EUR |0.25    |0.26      |-2.9       |
|                               |        |          |           |
|Biotechnology Division         |        |          |           |
|Sales revenue                  |90.6    |85.9      |+5.4 (+9.5)|
|Order intake                   |97.6    |99.1      |-1.5 (+2.2)|
|EBITA 1)                       |9.1     |8.4       |+8.5       |
|                               |        |          |           |
|Mechatronics Division          |        |          |           |
|Sales revenue                  |58.6    |57.7      |+1.5 (+5.1)|
|Order intake                   |64.9    |63.8      |+1.8 (+5.3)|
|EBITA 1)                       |3.1     |3.4       |-7.9       |

in parentheses: currency-adjusted 1) for 2007 underlying 2) excluding
non-cash amortization and, for 2008, additionally excluding non-cash 
interest expenses for share price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly 
results for Sartorius with analysts and investors in a teleconference
at 4:30 p.m. CET following today's Annual Shareholder Meeting. You 
may dial into this teleconference starting at 4:15 p.m. CET at the 
following numbers:

Germany: +49 (0)69 5007 1316;
France: +33 (0)1 70 99 42 99;
UK: +44 (0)20 7806 1968;
USA: +1 718 354 1387.

The dial-in code is 3601455;

to view the webcast, log onto www.livemeeting.com/cc/premconfeurope/j
oin?id=3601455&role=attend&pw=pw7076

end of announcement                               euro adhoc

Further inquiry note:

Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade